SCHEMBL1749370

SCHEMBL1749370

CC1CCN(c2ccc(C(=O)O)nc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.60
KMT2A Q03164 2/20 0.49
SMN1; SMN2 Q16637 4/20 0.46
HRH3 Q9Y5N1 5/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
KDM4E B2RXH2 3/20 0.44
GAA P10253 3/20 0.44
MAPT P10636 1/20 0.44
GLA P06280 1/20 0.44
HTT P42858 1/20 0.44
HIF1A Q16665 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MCL1 Q07820 1/20 0.44
ALDH1A1 P00352 2/20 0.43
POLB P06746 2/20 0.43
NR4A1 P22736 1/20 0.43
HSD17B10 Q99714 1/20 0.43
P4HA1 P13674 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26030060 0.84 USP2 (0.49) USP2SMN1; SMN2HRH3NPC1RAB9A
SCHEMBL24420935 0.84 KDM4E (0.43) USP2KMT2ASMN1; SMN2HRH3KDM4E
SCHEMBL29614700 0.84 KDM4E (0.43) USP2KMT2ASMN1; SMN2HRH3KDM4E
Hydrochloric Acid SCHEMBL26114917 0.82 KDM4E (0.42) USP2KMT2ASMN1; SMN2HRH3KDM4E
SCHEMBL1173393 0.82 MAPT (0.49) KMT2ASMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL63616 0.81 HDAC3 (0.54) KMT2ASMN1; SMN2NPC1RAB9AGAA
SCHEMBL3342623 0.81 MAPT (0.51) KMT2ASMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL724509 0.80 L3MBTL3 (0.55) KMT2ASMN1; SMN2HRH3KDM4EGLA
SCHEMBL28314039 0.80 HDAC3 (0.53) KMT2ASMN1; SMN2NPC1RAB9AGAA
SCHEMBL30379043 0.80 HRH3 (0.46) USP2KMT2ASMN1; SMN2HRH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-07-06 US disclosed
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments CYP11B2, CYP11B1, CYP1A1 USP2 3988/4885KMT2A 4317/4885SMN1; SMN2 1857/4885
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 USP2 4688/4885KMT2A 3819/4885SMN1; SMN2 1269/4885
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 USP2 3703/4885KMT2A 4320/4885SMN1; SMN2 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.